Tirumalai Kamala

PeerJ Author

Summary

A Ph.D. in Microbiology from India. Immunology training and research at the NIH, USA. Now a newly hatched founder of Tregeutix Inc., a biotech startup that focuses on developing microbiota guided antigen-specific immunotherapies. Science is not just a career, rather it's my vocation.

Biotechnology Immunology Infectious Diseases Microbiology

Work details

Founder, Director

Tregeutix Inc.

Websites

PeerJ Contributions

Preprints 3

July 11, 2019 - Version: 1

Shared TCR epitope cross-reactivity could permit dyads of Foxp3+ regulatory and IL-2-producing T cell precursors to escape thymic purge

David Usharauli, Tirumalai Kamala

https://doi.org/10.7287/peerj.preprints.27853v1

September 8, 2017 - Version: 1

Loss of microbiota depletes cross-reactive Foxp3⁺ Tregs leading to selective immunopathologies

Tirumalai Kamala, David Usharauli

https://doi.org/10.7287/peerj.preprints.3237v1

July 10, 2017 - Version: 1

An identical mechanism governs self-nonself discrimination and effector class regulation

David Usharauli, Tirumalai Kamala

https://doi.org/10.7287/peerj.preprints.3081v1